Inc. Innoviva,, a major owner of Theravance, recently acquired 3,731,025 shares of the company. The buys took place at $2.00 per share, on May 03, 2021. Innoviva, now owns 22,403,922 shares of the company. Innoviva, operates out of Burlingame, CA. Some additional info was provided as follows:
As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva, Inc. ("INVA") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA ("ISO" and together with INVA, the "Reporting Persons") with the U.S. Securities and Exchange Commission on May 3, 2021 (the "Schedule 13D/A"), in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the "Purchase Agreement" and, such closing, the "C losing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and ISO, ISO acquired 3,731,025 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 3,731,025 Shares ("Warrants" and together with the Shares, the "Security") for an aggregate price of $2.00 per Security as set forth in this Form 4.
INVA acquired an aggregate of 18,672,897 shares of common stock of the issuer and warrants to purchase an aggregate 18,672,897 shares of common stock of the Issuer in transactions on April 22, 2020, June 11, 2020 and September 1, 2020.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Theravance makes a similar move, sign up!
Other recent filings from the company include the following:
On October - Oct. 27, 2021
OrbiMed Genesis GP LLC just provided an update on activist position in Theravance - Oct. 19, 2021
James just provided an update on activist position in Theravance - Oct. 18, 2021
Major owner of Theravance just picked up 1,615,427 shares - Oct. 15, 2021
Major owner of Theravance just declared 0 ownership of the company. - Oct. 15, 2021